BioNxt Solutions Inc. (CVE:BNXT)

PRESS RELEASE

published on 01/19/2026 at 09:05, 2 months 3 days ago

BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
BioNxt Solutions reports successful comparative pharmacokinetics study in pigs for sublingual cladribine ODF formulation, showing superior bioavailability and potential benefits for Multiple Sclerosis therapy. Internal analysis ongoing

Multiple Sclerosis Drug Delivery BioNxt Solutions Cladribine ODF Comparative Pharmacokinetics
BRIEF

published on 12/17/2025 at 09:10, 3 months 5 days ago

BioNxt Advances with Rapid-Dissolving Drug Technology

Autoimmune Diseases Drug Delivery Patent Protection Thin-film Technology Dysphagia
BRIEF

published on 12/17/2025 at 09:10, 3 months 5 days ago

BioNxt fait des progrès dans le domaine des médicaments à dissolution rapide

Maladies Auto-immunes Administration De Médicaments Technologie Des Couches Minces Protection Par Brevet Dysphagie
PRESS RELEASE

published on 12/17/2025 at 09:05, 3 months 5 days ago

Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
BioNxt Solutions Inc. announces breakthrough in drug delivery for dysphagia, securing first national-level patent for thin-film platform, targeting autoimmune markets with bioequivalent cladribine treatment

BioNxt Solutions Inc. Drug Delivery Dysphagia Thin-film Platform Autoimmune Markets
BRIEF

published on 12/09/2025 at 09:10, 3 months 13 days ago

BioNxt Develops "Melt in Your Mouth" Cladribine for MS Patients

Multiple Sclerosis Cladribine BioNxt Solutions Melt In Your Mouth Drug-delivery
BRIEF

published on 12/09/2025 at 09:10, 3 months 13 days ago

BioNxt développe une cladribine « fondante » pour les patients atteints de SEP.

Sclérose En Plaques Cladribine Solutions BioNxt Administration De Médicaments Fond Dans La Bouche
PRESS RELEASE

published on 12/09/2025 at 09:05, 3 months 13 days ago

BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
BioNxt Solutions Inc. is developing a sublingual cladribine ODF to enhance MS treatment access. The innovative technology aims to improve swallowing difficulties and increase therapy adherence

BioNxt Solutions Inc. Multiple Sclerosis Drug Delivery Cladribine ODF Melt In Your Mouth
BRIEF

published on 12/01/2025 at 09:10, 3 months 21 days ago

BioNxt Solutions va acquérir la propriété intellectuelle d'un médicament de chimiothérapie sublinguale

Propriété Intellectuelle Chimiothérapie Solutions BioNxt Médicament Sublingual Marché Des Immunosuppresseurs
BRIEF

published on 12/01/2025 at 09:10, 3 months 21 days ago

BioNxt Solutions to Acquire IP for Sublingual Chemotherapy Drug

Intellectual Property Chemotherapy BioNxt Solutions Sublingual Drug Immunosuppressant Market
PRESS RELEASE

published on 12/01/2025 at 09:05, 3 months 21 days ago

BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
BioNxt Solutions collaborates with European chemotherapy company for novel sublingual drug formulation with high-potency ingredient. Focus on oncology and immunosuppressant treatments. Company plans to expand IP portfolio

Oncology BioNxt Solutions European Chemotherapy Company Sublingual Drug Formulation Immunosuppressant

Published on 03/20/2026 at 23:00, 1 day 18 hours ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 1 day 19 hours ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 1 day 19 hours ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 2 days 3 hours ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 4 hours ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals

View all ACCESSWIRE

Published on 03/22/2026 at 12:23, 4 hours 45 minutes ago

Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 18 hours ago

Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 20 hours ago

Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 20 hours ago

Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 21:00, 1 day 20 hours ago

BRP Unveils the Winners of its 6th International Design Challenge

View all EQS

Published on 03/20/2026 at 19:00, 1 day 22 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 1 day 22 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 1 day 22 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 1 day 22 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
Published on 03/20/2026 at 17:45, 1 day 23 hours ago

Cie du Bois Sauvage : Jaarverslag 2025

View all LES ECHOS COMFI WIRE

News